Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC SODIUM versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC SODIUM versus LODINE.
DICLOFENAC SODIUM vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis via inhibition of cyclooxygenase, leading to anti-inflammatory, analgesic, and antipyretic effects.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Oral: 50 mg two to three times daily; maximum 150 mg/day. Topical: 1% gel applied four times daily. Rectal: 100 mg suppository once daily.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.3–3.1 h). Short half-life requires frequent dosing; no accumulation with normal dosing intervals.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Approximately 65% renal as glucuronide conjugates and inactive metabolites, ~20% biliary/fecal. Less than 1% unchanged in urine.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID